BioCentury
ARTICLE | Company News

CAFC delays launch of Zarxio

May 7, 2015 2:30 AM UTC

The U.S. Court of Appeals for the Federal Circuit (CAFC) granted a motion from Amgen Inc. (NASDAQ:AMGN) for a preliminary injunction against the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) that will delay the launch of Zarxio filgrastim-sndz, a biosimilar of Amgen's Neupogen filgrastim, until the court resolves Amgen's appeal.

Amgen argued that it would suffer irreparable harm from price erosion upon Zarxio's launch. The CAFC did not provide a reason for its decision. ...